Skip Navigation


Annals of Oncology Advance Access originally published online on June 9, 2006
Annals of Oncology 2006 17(8):1296-1300; doi:10.1093/annonc/mdl122
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1296    most recent
mdl122v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zinzani, P. L.
Right arrow Articles by Baccarani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zinzani, P. L.
Right arrow Articles by Baccarani, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients

P. L. Zinzani1,*, M. Tani1, S. Fanti2, L. Alinari1, G. Musuraca1, E. Marchi1, V. Stefoni1, P. Castellucci2, M. Fina1, M. Farshad2, S. Pileri1 and M. Baccarani1

1 Institute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna; 2 Nuclear Medicine, S'Orsola Hospital, Bologna, Italy

* Correspondence to: Dr P. L. Zinzani, Istituto di Ematologia e Oncologia Medica ‘L. & A. Seràgnoli’, Policlinico S. Orsola – Malpighi, Via Massarenti 9, 40138, Bologna, Italy. Tel: +39 051 636 3680; Fax: +39 051 636 4037; E-mail: plzinzo{at}med.unibo.it

Background: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients.

Patients and Methods: Between June 2003–September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles. All these patients underwent staging/restaging: computed tomography (CT) and positron emission tomography (PET) at time 0, PET after two cycles, CT and PET after four and six cycles.

Results: After two cycles (PET-2), the PET was negative in 28/40 (70%), positive in 8/40 (20%), and minimal residual uptake (MRU) was present in the remaining four (10%) patients. After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months. All four patients with MRU at the PET-2 became PET_ during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months. All 28 PET negative patients at the PET-2 remained PET negative and all of them were in CR after treatment.

Conclusions: The PET use for early (after two cycles) response assessment in HD patients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.

Key words: chemotherapy, early response, HD, PET


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. Furth, I. G. Steffen, H. Amthauer, J. Ruf, D. Misch, S. Schonberger, C. Kobe, T. Denecke, B. Stover, H. Hautzel, et al.
Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial
J. Clin. Oncol., September 10, 2009; 27(26): 4385 - 4391.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Avigdor, S. Bulvik, I. Levi, E. J. Dann, N. Shemtov, G. Perez-Avraham, A. Shimoni, A. Nagler, I. Ben-Bassat, and A. Polliack
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma
Ann. Onc., July 16, 2009; (2009) mdp271v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Markova, C. Kobe, M. Skopalova, K. Klaskova, K. Dedeckova, A. Plutschow, H. T. Eich, M. Dietlein, A. Engert, and T. Kozak
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
Ann. Onc., July 1, 2009; 20(7): 1270 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Hutchings and S. F. Barrington
PET/CT for Therapy Response Assessment in Lymphoma
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Terasawa, J. Lau, S. Bardet, O. Couturier, T. Hotta, M. Hutchings, T. Nihashi, and H. Nagai
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
J. Clin. Oncol., April 10, 2009; 27(11): 1906 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Luigi Zinzani, V. Stefoni, M. Tani, S. Fanti, G. Musuraca, P. Castellucci, E. Marchi, M. Fina, V. Ambrosini, C. Pellegrini, et al.
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
J. Clin. Oncol., April 10, 2009; 27(11): 1781 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Kobe, M. Dietlein, J. Franklin, J. Markova, A. Lohri, H. Amthauer, S. Klutmann, W. H. Knapp, J. M. Zijlstra, A. Bockisch, et al.
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Blood, November 15, 2008; 112(10): 3989 - 3994.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein
Imaging in staging of malignant lymphoma: a systematic review
Blood, January 15, 2008; 111(2): 504 - 516.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood, November 15, 2007; 110(10): 3507 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Gallamini, M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, C. Patti, A. Loft, F. Di Raimondo, F. D'Amore, et al.
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
J. Clin. Oncol., August 20, 2007; 25(24): 3746 - 3752.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
P. L. Zinzani, M. Tani, R. Trisolini, S. Fanti, V. Stefoni, M. Alifano, P. Castellucci, G. Musuraca, G. Dalpiaz, L. Alinari, et al.
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
Haematologica, June 1, 2007; 92(6): 771 - 777.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al.
Revised Response Criteria for Malignant Lymphoma
J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. J. Horning
Risk, Cure and Complications in Advanced Hodgkin Disease
Hematology, January 1, 2007; 2007(1): 197 - 203.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.